We use our own cookies and third-party cookies to improve our services and analyse the browsing habits of our users. Continuing to browse our sites implies full acceptance of their use. You can change your cookie setting or get more information here
PhD in chemistry from the University of the Balearic Islands (UIB), founder and CEO of Sanifit Laboratory, biotechnology company focused on the development of drugs, was president of the Balearic Association of Biotechnological Companies (2008-2010) and currently serves as president of the Balearic Islands Cluster of Biotechnology (2010-present) besides being the vice-rector of the College of Chemists of the Balearic Islands (2009-present). He has managed to get more than 10M € of funding (public + private) in Sanifit and two out-licensing agreements in the areas of consumer health and medical technology.
National Award for the best doctoral thesis in urolithiasis (2005, Spain).
Several awards on national and regional research and innovation.
Adjunct professor at the University of the Balearic Islands since 2006.
Co-author of more than 40 international scientific publications and in more than 50 conferences, co-inventor of 9 international patents, has participated in 30 research projects, PI being half of them.
Fernando Barrera Barceló
Name: Fernando Barrera
Organization: CIRCE Crystal Engineering / UIB
CIRCE Crystal Engineering CEO. Founder partner of Mediterranean Life Pharma. Fourteen years of experience in technology transfer activities and project management of R & D as Head of the Office of Technology Transfer at the UIB. He has managed and directed more than twenty national and international projects in the field of technology transfer and creation of knowledge-based companies. University degree in Physical Sciences, specialist in business management from the UIB and Project Management by the UPC.
Massimo De Faveri
Name: Massimo De Faveri
Juan Vicente Torres Martín
Name: Juan Vicente Torres
Position: Head of Biometry
Organization: Syntax for Science
Juan Vicente Torres is biostatistician with more than 10 years of experience in drug development. His experience spans through multiple therapeutic areas and includes all phases of clinical development. He has contributed to the planning, design, and development of successful projects for methodological and statistical aspects in collaboration with leading pharmaceutical companies like Hoffmann-La Roche, Merck, and Actelion Pharmaceuticals.
Juan Vicente is founder member of the Catalonian Statistical Society, and active member of the Spanish Biometric Society, and the International Society of Clinical Biostatistics (ISCB). Member of the Statistics in Regulatory Affairs Sub-Committee of the ISCB Society.
Alexander Damià Heine Suñer
Name: Damià Heine Suñer
Position: Scientific director and partner
Dr Damian Heine Suñer was born in 1963 in New York City, USA. He followed his studies in biology at the University of Barcelona, Spain. He received a joint PhD degree from Rutgers University and the University of Medicine and Dentistry of New Jersey (UMDNJ), USA, in 1995. From 1995 to 1999, Dr Heine Suñer held a postdoctoral position in the laboratory of Dr. Santiago Rodríguez de Cordoba in Madrid (Spain), at the Centro de Investigaciones Biológicas (CIB), a research center within the Spanish National Research Council (CSIC). In Madrid, his research continued to be focused on the genetics and genomics of recombination, and now, on how it is implicated in human disease.
In 1999 Dr. Heine Suñer returned to his home island, Mallorca (Spain) to set up the Molecular Genetics Clinical Diagnostic Laboratory within the Genetics Department of the Hospital Son Dureta (currently Hospital Universitari Son Espases, HUSE). The Genetics Department of Hospital Son Espases is the only one offering clinical genetic services within the public health system of the Balearic Islands (IB-Salut) and services a population of 1.100.000. Also in 1999, he received his first competitive research grant as a Principal Investigator (PI), from the Spanish Ministry of Health to study the molecular basis of the 22q11DS. And since then has been continuously funded and maintained an active research interest in genomics of health in general, and the 22q11DS syndrome, congenital heart defects and Fragile-X syndrome in particular. Currently, research projects entail and prioritize the use of new technologies for the study of these diseases (SNP-arrays, NGS and digital PCR).
In 2012 he was co-founder of the spin-off genetic diagnostic and research and development company, Genosalut, of which he is scientific director and consultant. The facilities of the company are within one of the main private hospitals in Palma, Clinica Rotger, where it performs also as its Genetics Department. The company aims to apply next generation technologies to develop a personalized medicine approach for common and rare diseases. In this context, it has developed novel diagnostic strategies for the genetics of obesity, fitness and sport, as well as applying exome analysis to finding the genetic causes of cancer, epilepsy and rare diseases.
Currently he divides his time between his clinical diagnostic work as laboratory manager of the Molecular Genetics Diagnostics Laboratory of HUSE, his research activities and Genosalut. He is PI of the Genomics of Health Research Group that is englobed within the newly formed Institute for Research in Health of Palma (IDISPA). The main interests within the research group are molecular mechanisms leading to mutation in the human genome and the genetic basis of congenital heart defects (CDH), 22q11DS and Fragile X Syndrome (FXS). To date he has (co) authored more than 40 research papers.
Name: Luis Vegas
Organization: Fundació Universitat Empresa de les Illes Balears
Name: Ana Carvajal
Position: Quality department Manager
BIOIB Cluster biotecnològic i biomèdic de les Illes Balears
Edifici Empresarial Son Espanyol Local 9, 2ª Planta